Literature DB >> 29335212

Synthesis and biological evaluation of novel bavachinin analogs as anticancer agents.

Nidhi Gupta1, Arem Qayum2, Arun Raina3, Ravi Shankar3, Sumeet Gairola4, Shashank Singh2, Payare L Sangwan5.   

Abstract

A library of 28 analogs of bavachinin including aliphatic and aromatic ethers, epoxide, chalcone, oxime, semicarbazide, oxime ether and triazole derivatives have been synthesized and evaluated for cytotoxicity against four different human cancer cell lines. Bio-evaluation studies exhibited better cytotoxic profile for many analogs compare to bavachinin. Best results were observed for a 1,2,3-triazole analog (17i) with IC50 values 7.72, 16.08, 7.13 and 11.67 μM against lung (A549), prostate (PC-3), colon (HCT-116) and breast (MCF-7) cancer cell lines respectively. This analog showed three and four fold improvement in cytotoxicity against HCT-116 and A549 cell lines than parent molecule (1). Structure activity relationship (SAR) study for all synthesized analogs was carried out. Further, mechanistic study of the lead molecule (17i) revealed that it inhibits colony formation and in vitro migration of human colon cancer cells (HCT-116). Also, it induced the morphological changes and mediated the apoptotic cell death of HCT-116 cells with perturbance in mitochondrial membrane potential (MMP) and PARP cleavage.
Copyright © 2018 Elsevier Masson SAS. All rights reserved.

Entities:  

Keywords:  Bavachinin; Colony formation; Cytotoxicity; In-vitro migration; MMP; PARP

Mesh:

Substances:

Year:  2018        PMID: 29335212     DOI: 10.1016/j.ejmech.2018.01.006

Source DB:  PubMed          Journal:  Eur J Med Chem        ISSN: 0223-5234            Impact factor:   7.088


  8 in total

1.  A bavachinin analog, D36, induces cell death by targeting both autophagy and apoptosis pathway in acute myeloid leukemia cells.

Authors:  Wen Zhang; Jingwen Liu; Yiming Li; Fujiang Guo
Journal:  Cancer Chemother Pharmacol       Date:  2022-08-12       Impact factor: 3.288

2.  Potential metabolism determinants and drug-drug interactions of a natural flavanone bavachinin.

Authors:  Xinqiang Li; Han Xing; Zifei Qin; Jing Yang; Peile Wang; Xiaojian Zhang; Zhihong Yao; Xinsheng Yao
Journal:  RSC Adv       Date:  2020-09-23       Impact factor: 4.036

Review 3.  1,2,3-Triazole-containing hybrids as leads in medicinal chemistry: A recent overview.

Authors:  Khurshed Bozorov; Jiangyu Zhao; Haji A Aisa
Journal:  Bioorg Med Chem       Date:  2019-07-04       Impact factor: 3.641

4.  Study on the 2-Phenylchroman-4-One Derivatives and their anti-MERS-CoV Activities.

Authors:  Ji Hye Yoon; Jihye Lee; Jun Young Lee; Young Sup Shin; Dong Eon Kim; Jung Sun Min; Chul Min Park; Jong Hwan Song; Seungtaek Kim; Sunoh Kwon; Min Seong Jang; Hyoung Rae Kim
Journal:  Bull Korean Chem Soc       Date:  2019-07-28

Review 5.  Recent Advances in Bioactive Flavonoid Hybrids Linked by 1,2,3-Triazole Ring Obtained by Click Chemistry.

Authors:  Daniela Pereira; Madalena Pinto; Marta Correia-da-Silva; Honorina Cidade
Journal:  Molecules       Date:  2021-12-30       Impact factor: 4.411

6.  Alkyne-Tagged Apigenin, a Chemical Tool to Navigate Potential Targets of Flavonoid Anti-Dengue Leads.

Authors:  Kowit Hengphasatporn; Benyapa Kaewmalai; Somruedee Jansongsaeng; Vishnu Nayak Badavath; Thanaphon Saelee; Thamonwan Chokmahasarn; Tanatorn Khotavivattana; Yasuteru Shigeta; Thanyada Rungrotmongkol; Siwaporn Boonyasuppayakorn
Journal:  Molecules       Date:  2021-11-18       Impact factor: 4.411

7.  Synthesis and Antitumor Activity of 1-Substituted 1,2,3-Triazole-Mollugin Derivatives.

Authors:  Han Luo; Yong-Feng Lv; Hong Zhang; Jiang-Miao Hu; Hong-Mei Li; Shou-Jin Liu
Journal:  Molecules       Date:  2021-05-28       Impact factor: 4.411

Review 8.  1,2,3-Triazole-Containing Compounds as Anti-Lung Cancer Agents: Current Developments, Mechanisms of Action, and Structure-Activity Relationship.

Authors:  Ting Liang; Xiangyang Sun; Wenhong Li; Guihua Hou; Feng Gao
Journal:  Front Pharmacol       Date:  2021-06-11       Impact factor: 5.810

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.